RxDoctor Payments Data

Miranda Thurman, APRN

Family · East Prairie, MONPI 1891074274

Payments from drug & device makers

$1,388in general payments, 2019–2025

Across 79 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$221
  • AbbVie$209
  • Lilly USA, LLC$206
  • Amgen$198
  • Dexcom, Inc.$88
  • Idorsia Pharmaceuticals US Inc$55
  • plus $411 from 16 others

What the payments were for

  • Food & beverage$1,36999%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,388 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$4,301
Medicare patients
136
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$73,674
EliquisApixaban77$47,918
RexultiBrexpiprazole22$32,185
FarxigaDapagliflozin Propanediol37$25,342
MounjaroTirzepatide21$23,477
JardianceEmpagliflozin30$21,254
JanuviaSitagliptin Phosphate31$20,708
MyrbetriqMirabegron39$19,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,597
TradjentaLinagliptin24$13,610
Repatha SureclickEvolocumab21$11,538
XareltoRivaroxaban13$11,509
Combivent RespimatIpratropium/Albuterol Sulfate23$11,121
TrulicityDulaglutide11$10,814
LinzessLinaclotide15$9,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$221$73,67472 claims
PfizerEliquis, Abrysvo$33$52,20491 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$48$45,98577 claims
Lilly USA, LLCMounjaro, Trulicity$206$34,29032 claims
AstraZenecaFarxiga, Symbicort$14$31,45863 claims
MerckJanuvia$17$20,70831 claims
AbbVieLinzess, Synthroid$209$10,15934 claims
NovartisEntresto$31$8,03412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in East Prairie

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →